Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 33.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 48,458 shares of the biopharmaceutical company’s stock after selling 24,801 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Alnylam Pharmaceuticals were worth $11,775,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of the stock. V Square Quantitative Management LLC lifted its holdings in Alnylam Pharmaceuticals by 21.9% in the second quarter. V Square Quantitative Management LLC now owns 334 shares of the biopharmaceutical company’s stock worth $81,000 after purchasing an additional 60 shares during the period. Commerce Bank lifted its holdings in Alnylam Pharmaceuticals by 1.7% in the fourth quarter. Commerce Bank now owns 4,683 shares of the biopharmaceutical company’s stock worth $896,000 after purchasing an additional 77 shares during the period. Envestnet Portfolio Solutions Inc. lifted its holdings in Alnylam Pharmaceuticals by 7.0% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 1,368 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 89 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in Alnylam Pharmaceuticals by 54.2% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 259 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 91 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC acquired a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at about $26,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

ALNY has been the subject of a number of research analyst reports. Royal Bank of Canada reissued an “outperform” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 4th. Canaccord Genuity Group upped their price target on shares of Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Needham & Company LLC boosted their price objective on Alnylam Pharmaceuticals from $275.00 to $320.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. The Goldman Sachs Group upgraded Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $198.00 to $370.00 in a report on Friday, August 16th. Finally, Bank of America boosted their price objective on Alnylam Pharmaceuticals from $295.00 to $307.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. Seven investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $279.14.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $265.27 on Friday. The stock has a market cap of $34.06 billion, a price-to-earnings ratio of -98.98 and a beta of 0.38. The business has a 50 day simple moving average of $258.53 and a 200 day simple moving average of $194.56. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $287.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.61. The firm had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. The company’s quarterly revenue was up 107.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($2.21) EPS. On average, analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 32,450 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the completion of the sale, the director now owns 136 shares of the company’s stock, valued at $30,013.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 2,103 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $485,771.97. Following the completion of the sale, the chief marketing officer now owns 15,609 shares of the company’s stock, valued at $3,605,522.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David E. I. Pyott sold 32,450 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $220.69, for a total value of $7,161,390.50. Following the sale, the director now directly owns 136 shares of the company’s stock, valued at approximately $30,013.84. The disclosure for this sale can be found here. In the last quarter, insiders sold 103,148 shares of company stock valued at $25,658,824. 1.50% of the stock is owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.